Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. November 2022 08:00 ET | Quelle: Aramis Biosciences

Aramis Biosciences Completes Enrollment of its Phase II Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease

BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced the completion of enrollment in its Phase II...
28. Februar 2022 08:00 ET | Quelle: Aramis Biosciences

Aramis Biosciences Announces First Patient Dosed in Phase II Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease

BOSTON, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced that the first patient has been dosed in its...
11. Januar 2022 08:00 ET | Quelle: Aramis Biosciences

Aramis Biosciences Announces FDA Clearance of IND Application for A197, a Novel Immunomodulatory Agent for the Treatment of Dry Eye Disease

BOSTON, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)...
15. Dezember 2021 08:00 ET | Quelle: Aramis Biosciences

Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunology

Founded by Renowned Experts in Ophthalmology and Immunology Launches with $10.5 million Series A Financing Led by Safar Partners to Advance Disease-Modifying Therapy for Ocular Surface Disease into...